We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Proteomic Testing May Enable NIV Diagnosis of Respiratory Pathologies in Preterm Newborns

By LabMedica International staff writers
Posted on 19 Sep 2016
A team of researchers is developing its new method for noninvasive diagnosis and therapeutic response monitoring of conditions in preterm newborns based on marker sets now identified by proteome analysis of urine samples.

The majority of patients in neonatal intensive care units are premature babies, who often have respiratory conditions. More...
It is important to distinguish whether their illness is due to infection or a failure in the developmental process. The composition of biological fluids (e.g. blood, urine, saliva) is highly complex, and most current diagnostic procedures for neonatal intensive therapy include sample collections that are invasive (e.g. biopsy) or semi-invasive (e.g. blood sampling).

Using high-performance mass spectrometry (HPMS; more specifically LC-MS/MS), experts from the Moscow Institute of Physics and Technology (MIPT; Moscow, Russia) are identifying different proteins and determining their concentrations in target fluids. Studies of the urinary proteome in pediatrics, especially in neonatology, are limited. In the new study, the team investigated the urine proteome of preterm newborns with respiratory pathologies. In order to further specify the defined infant-specific dataset, proteins were compared with the urinary proteome of healthy adults (men and pregnant women).

As a result bioinformatic processing of the HPMS data, the team singled out 36 proteins that indicate if respiratory pathologies are infectious (congenital pneumonia) or non-infectious (tachypnea, infant respiratory distress syndrome).

“In our pilot study, we succeeded in defining the core urinary proteome and proteins specific for infants and pathological conditions. We are pioneers in the non-invasive identification of urinary biomarkers diagnosing respiratory conditions in newborns. The results are optimistic and will serve as a platform to move forward in developing a method of monitoring conditions in newborns,” said team leader Prof. Evgeny Nikolaev, head of MIPT’s Laboratory of Ionic and Molecular Physics.

The study, by Starodubtseva NL, Kononikhin AS, et al, was published June 14, 2016, online ahead of print in the Journal of Proteomics.

Related Links:
Moscow Institute of Physics and Technology


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.